Synergistic Role of Self-Emulsifying Lipids and Nanostructured Porous Silica Particles in Optimizing The Oral Delivery of Lovastatin

References

• Schachter M . Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam. Clin. Pharmacol.19 (1), 117–125 (2005).
   PubMed Web of Science ®Google Scholar
• Zhu Y , D'AgostinoJ, ZhangQ-Y. Role of intestinal cytochrome P450 (P450) in modulating the bioavailability of oral lovastatin: insights from studies on the intestinal epithelium-specific P450 reductase knockout mouse. Drug Metab. Dispos.39 (6), 939–943 (2011).
   PubMed Web of Science ®Google Scholar
• Moghadasian MH . Clinical pharmacology of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Life Sci.65 (13), 1329–1337 (1999).
   PubMed Web of Science ®Google Scholar
• Ochoa L , IgartuaM, HernándezRM, GascónAR, SolinisMA, PedrazJL. Novel extended-release formulation of lovastatin by one-step melt granulation: in vitro and in vivo evaluation. Eur. J. Pharm. Biopharm.77 (2), 306–312 (2011).
   PubMed Web of Science ®Google Scholar
• Ge Z , ZhangX-X, GanL, GanY. Redispersible, dry emulsion of lovastatin protects against intestinal metabolism and improves bioavailability. Acta Pharmacol. Sin.29 (8), 990–997 (2008).
   PubMed Web of Science ®Google Scholar
• Suresh G , ManjunathK, VenkateswarluV, SatyanarayanaV. Preparation, characterization, and in vitro and in vivo evaluation of lovastatin solid lipid nanoparticles. AAPS PharmSciTech8 (1), e162–e170 (2007).
   Web of Science ®Google Scholar
• Chen C-C , TsaiT-H, HuangZ-R, FangJ-Y. Effects of lipophilic emulsifiers on the oral administration of lovastatin from nanostructured lipid carriers: physicochemical characterization and pharmacokinetics. Eur. J. Pharm. Biopharm.74 (3), 474–482 (2010).
   PubMed Web of Science ®Google Scholar
• Pouton CW . Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system. Eur. J. Pharm. Sci.29 (3–4), 278–287 (2006).
   PubMed Web of Science ®Google Scholar
• Shah NH , PhuapraditW, ZhangY-E, AhmedH, MalickAW. Lipid-based isotropic solutions: design considerations. In : Oral Lipid-Based Formulations.HaussDJ ( Ed.). Informa Healthcare, NY, USA, 129–148 (2007).
   Google Scholar
• Tan A , RaoS, PrestidgeC. Transforming lipid-based oral drug delivery systems into solid dosage forms: an overview of solid carriers, physicochemical properties, and biopharmaceutical performance. Pharm. Res.30 (12), 2993–3017 (2013).
   PubMed Web of Science ®Google Scholar
• Santos HA , HirvonenJ. Nanostructured porous silicon materials: potential candidates for improving drug delivery. Nanomedicine (Lond.)7 (9), 1281–1284 (2012).
   PubMed Web of Science ®Google Scholar
• Liu J , Stace-NaughtonA, JiangX, BrinkerCJ. Porous nanoparticle supported lipid bilayer (protocells) as delivery vehicles. J. Am. Chem. Soc.131 (4), 1354–1355 (2009).
   PubMed Web of Science ®Google Scholar
• Simovic S , BarnesTJ, TanA, PrestidgeCA. Assembling nanoparticle coatings to improve the drug delivery performance of lipid based colloids. Nanoscale4 (4), 1220–1230 (2012).
   PubMed Web of Science ®Google Scholar
• Bremmell KE , TanA, MartinA, PrestidgeCA. Tableting lipid-based formulations for oral drug delivery: a case study with silica nanoparticle–lipid–mannitol hybrid microparticles. J. Pharm. Sci.102 (2), 684–693 (2013).
   PubMed Web of Science ®Google Scholar
• Tan A , PrestidgeC. Nanostructured silica–lipid hybrid microparticles: a supersaturating carrier for water- and lipid-resistant compounds. Chem. Lett.41 (10), 1334–1336 (2012).
   Web of Science ®Google Scholar
• Daum N , TschekaC, NeumeyerA, SchneiderM. Novel approaches for drug delivery systems in nanomedicine: effects of particle design and shape. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol.4 (1), 52–65 (2012).
   PubMed Web of Science ®Google Scholar
• Tan A , MartinA, NguyenT-H, BoydBJ, PrestidgeCA. Hybrid nanomaterials that mimic the food effect: controlling enzymatic digestion for enhanced oral drug absorption. Angew. Chem. Int. Ed. Engl.124 (22), 5571–5575 (2012).
   Google Scholar
• Tan A , SimovicS, DaveyAK, RadesT, BoydBJ, PrestidgeCA. Silica nanoparticles to control the lipase-mediated digestion of lipid-based oral delivery systems. Mol. Pharm.7 (2), 522–532 (2010).
   PubMed Web of Science ®Google Scholar
• Simovic S , HeardP, HuiHet al. Dry hybrid lipid−silica microcapsules engineered from submicron lipid droplets and nanoparticles as a novel delivery system for poorly soluble drugs. Mol. Pharm.6 (3), 861–872 (2009).
   PubMed Web of Science ®Google Scholar
• Tan A , SimovicS, DaveyAK, RadesT, PrestidgeCA. Silica–lipid hybrid (SLH) microcapsules: a novel oral delivery system for poorly soluble drugs. J. Control. Release134 (1), 62–70 (2009).
   PubMed Web of Science ®Google Scholar
• Nguyen T-H , TanA, SantosLet al. Silica–lipid hybrid (SLH) formulations enhance the oral bioavailability and efficacy of celecoxib: an in vivo evaluation. J. Control. Release167, 85–91 (2013).
   PubMed Web of Science ®Google Scholar
• Tan A , EskandarN, RaoS, PrestidgeC. First in man bioavailability and tolerability studies of a silica–lipid hybrid (Lipoceramic) formulation: a Phase I study with ibuprofen. Drug Deliv. Transl. Res.4, 212–222 (2014).
   PubMed Web of Science ®Google Scholar
• Anby MU , WilliamsHD, McIntoshMet al. Lipid digestion as a trigger for supersaturation: evaluation of the impact of supersaturation stabilization on the in vitro and in vivo performance of self-emulsifying drug delivery systems. Mol. Pharm.9 (7), 2063–2079 (2012).
   PubMedGoogle Scholar
• Santhanam N , ConfortiTA, SpiekerW, RegalbutoJR. Nature of metal catalyst precursors adsorbed onto oxide supports. Catal. Today21 (1), 141–156 (1994).
   Web of Science ®Google Scholar
• Jesionowski T , PokoraM, SobaszkiewiczK, PernakJ. Preparation and characterization of functionalized precipitated silica SYLOID® 244 using ionic liquids as modifiers. Surf. Interface Anal.36 (11), 1491–1496 (2004).
   Web of Science ®Google Scholar
• Tan A , DaveyA, PrestidgeC. Silica–lipid hybrid (SLH) versus non-lipid formulations for optimising the dose-dependent oral absorption of celecoxib. Pharm. Res.28 (9), 2273–2287 (2011).
   PubMed Web of Science ®Google Scholar
• Cuine JF , McevoyCL, CharmanWNet al. Evaluation of the impact of surfactant digestion on the bioavailability of danazol after oral administration of lipidic self-emulsifying formulations to dogs. J. Pharm. Sci.97, 995–1012 (2008).
   PubMed Web of Science ®Google Scholar
• Chambin OJV . Interest of multifunctional lipid excipients: case of Gelucire® 44/14. Drug Dev. Ind. Pharm.31 (6), 527–534 (2005).
   PubMed Web of Science ®Google Scholar
• Date AA , DesaiN, DixitR, NagarsenkerM. Self-nanoemulsifying drug delivery systems: formulation insights, applications and advances. Nanomedicine (Lond.)5 (10), 1595–1616 (2010).
   PubMed Web of Science ®Google Scholar
• Porter CJH , KaukonenAM, BoydBJ, EdwardsGA, CharmanWN. Susceptibility to lipase-mediated digestion reduces the oral bioavailability of danazol after administration as a medium-chain lipid-based microemulsion formulation. Pharm. Res.21, 1405–1412 (2004).
   PubMed Web of Science ®Google Scholar
• Sek L , BoydBJ, CharmanWN, PorterCJH. Examination of the impact of a range of pluronic surfactants on the in-vitro solubilisation behaviour and oral bioavailability of lipidic formulations of atovaquone. J. Pharm. Pharmacol.58, 809–820 (2006).
   PubMed Web of Science ®Google Scholar
• Thomas N , HolmR, MüllertzA, RadesT. In vitro and in vivo performance of novel supersaturated self-nanoemulsifying drug delivery systems (super-SNEDDS). J. Control. Release160 (1), 25–32 (2012).
   PubMed Web of Science ®Google Scholar
• Wu CY , BenetLZ. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm. Res.22 (1), 11–23 (2005).
   PubMed Web of Science ®Google Scholar